EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study

Jane Gakuru iD, Enock Kagimu iD, Biyue Dai, Samuel Okurut, Laura Nsangi, Nathan C Bahr, Michael Okirwoth, Olivie C Namuju, Joseph N Jarvis, David S Lawrence, Cynthia Ahimbisibwe, Jayne Ellis und 4 weitere

Clinical Infectious Diseases · 24.02.2025 · 80 (2) · 417-424

DOI: 10.1093/cid/ciae413 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 24.08.2024. Verfasst von Jane Gakuru und 15 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: AIDS-Related Opportunistic Infections, Amphotericin B, Antifungal Agents, HIV Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Wellcome Trust via the Joint Global Health Trials, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In 2022, the World Health Organization (WHO) recommended a single 10 mg/kg dose of liposomal amphotericin B in combination with 14 days of flucytosine and fluconazole (AMBITION-cm regimen) for induction therapy of human immunodeficiency virus (HIV)-associated cryptococcal meningitis, based on the results of the multisite AMBITION-cm trial. We evaluated outcomes after real-world implementation of this novel regimen in Uganda.

Methods

We enrolled Ugandan adults with cryptococcal meningitis into an observational cohort receiving the AMBITION-cm regimen with therapeutic lumbar punctures in routine care during 2022–2023. We compared 10-week survival and CSF early fungicidal activity with the outcomes observed in the AMBITION-cm clinical trial conducted at the same sites.

Results

During 2022–2023, 179 adults were treated with the AMBITION-cm regimen via routine care and compared to the 171 adults randomized to the AMBITION-cm trial interventional arm in Uganda from 2018 to 2021. No significant difference in 10-week survival occurred between the observational cohort (68.6%; 95% confidence interval [CI]: 61.6%–76.3%) and AMBITION-cm trial participants in the intervention arm (71.7%; 95% CI: 65.2%–78.8%; absolute risk difference = −3.1%; 95% CI: −13.1% to 6.9%; P = .61). Early fungicidal activity did not differ (0.42 vs 0.39 log10CFU/mL/day; P = .80) between groups. Among observational cohort participants discharged alive initially and for whom follow-up data were available, the incidence of re-hospitalizations due to persistently elevated intracranial pressure was 2.8% (4/144).

Conclusions

The AMBITION-cm regimen for cryptococcal meningitis resulted in similar outcomes as observed in the AMBITION-cm clinical trial when implemented in routine care. Intracranial pressure management during hospitalization and awareness after discharge are key components of optimizing outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS-Related Opportunistic InfectionsAmphotericin BAntifungal AgentsHIV InfectionsMeningitis, CryptococcalAdultFemaleHumansMaleMiddle AgedYoung AdultDrug Therapy, CombinationFluconazoleFlucytosineInduction ChemotherapyProspective StudiesTreatment OutcomeUgandaClinical Trials, Phase III as TopicEquivalence Trials as Topic

Stichwörter der Autor:innen

HIVadvanced HIV diseasecryptococcal meningitisimplementationliposomal amphotericin B

Substanzen

Amphotericin BAntifungal AgentsFluconazoleFlucytosineliposomal amphotericin B

Autor:innen und Institutionen

  • Infectious Diseases Institute, Makerere University, Kampala, Uganda.
  • Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Botswana Harvard Health Partnership, Gaborone, Botswana.
  • School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Jane Gakuru, Enock Kagimu, David R Boulware, David B Meya

Förderung

  • NINDS NIH HHS
  • Wellcome Trust via the Joint Global Health Trials
  • NIAID NIH HHS
  • European and Developing Countries Clinical Trials Partnership
  • Wellcome Trust
  • United Kingdom Government
  • Swedish International Development Cooperation Agency
  • UK Foreign Commonwealth and Development Office

Zitieren

APA

Gakuru, J., Kagimu, E., Dai, B., Okurut, S., Nsangi, L., Bahr, N. C., Okirwoth, M., Namuju, O. C., Jarvis, J. N., Lawrence, D. S., Ahimbisibwe, C., Ellis, J., Tadeo, K. K., Boulware, D. R., Meya, D. B., & Tugume, L. (2025). Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study. Clinical Infectious Diseases, 80(2), 417-424. https://doi.org/10.1093/cid/ciae413

Vancouver

Gakuru J, Kagimu E, Dai B, Okurut S, Nsangi L, Bahr NC, et al. Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study. Clinical Infectious Diseases. 2025;80(2):417-424. doi:10.1093/cid/ciae413

BibTeX
@article{Gakuru2025,
  author = {Gakuru, Jane and Kagimu, Enock and Dai, Biyue and Okurut, Samuel and Nsangi, Laura and Bahr, Nathan C and Okirwoth, Michael and Namuju, Olivie C and Jarvis, Joseph N and Lawrence, David S and Ahimbisibwe, Cynthia and Ellis, Jayne and Tadeo, Kizza Kandole and Boulware, David R and Meya, David B and Tugume, Lillian},
  title = {Implementation of Single High-dose Liposomal Amphotericin B Based Induction Therapy for Treatment of HIV-associated Cryptococcal Meningitis in Uganda: A Comparative Prospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {2},
  pages = {417--424},
  doi = {10.1093/cid/ciae413}
}
Kostenlos starten →